Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SCD | O00767 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 8/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11611674 | 0.85 | SCD (0.51) | KDM4ESCDMAPK1PAK1ALDH1A1 | |
| SCHEMBL20089108 | 0.84 | SCD (0.50) | KDM4ESCDMAPK1PAK1ALDH1A1 | |
| SCHEMBL2508000 | 0.83 | SCD (0.49) | KDM4ESCDSRCALDH1A1TSHR | |
| SCHEMBL3722451 | 0.77 | PIK3CA (0.49) | PIK3CDPIK3CAPIK3CBKDM4EMAPK1 | |
| SCHEMBL30677292 | 0.75 | KDM4E (0.49) | PIK3CDPIK3CAPIK3CBKDM4ESRC | |
| SCHEMBL336705 | 0.75 | KDM4E (0.49) | PIK3CDPIK3CAPIK3CBKDM4ESRC | |
| SCHEMBL3322529 | 0.74 | CHEK1 (0.64) | PIK3CASRCMAPK1CHEK1PDPK1 | |
| SCHEMBL4243835 | 0.74 | KDM4E (0.48) | PIK3CDPIK3CAPIK3CBKDM4EMAPK1 | |
| SCHEMBL31069504 | 0.73 | SRC (0.58) | PIK3CDPIK3CAPIK3CBKDM4ESRC | |
| SCHEMBL1286633 | 0.72 | PIK3CA (0.50) | PIK3CDPIK3CAPIK3CBKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024014885-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | 일동제약(주) | 2024-01-18 | — | — | WO | claimed |
| CN-112939979-A | 2-morpholine purine derivative, preparation method thereof and application thereof in antitumor drugs | 林剑雄 | 2021-06-11 | — | — | CN | claimed |
| WO-2024014885-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | 일동제약(주) | 2024-01-18 | — | — | WO | disclosed |
| EP-4161519-A1 | PURINES AND METHODS OF THEIR USE | Yumanity Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2023-01-03 | — | — | US | disclosed |
| CN-112939979-A | 2-morpholine purine derivative, preparation method thereof and application thereof in antitumor drugs | 林剑雄 | 2021-06-11 | — | — | CN | disclosed |
| CN-103003279-B | Purine compounds selective for PI3K P110 and methods of use thereof | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-23 | — | — | CN | disclosed |
| CN-102459272-B | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH INC | 2014-08-06 | — | — | CN | disclosed |
| CN-102245607-B | Morpholinopurine derivative | DAIICHI SANKYO CO LTD | 2014-07-02 | — | — | CN | disclosed |
| CN-102105474-B | Purine PI3K inhibitor compounds and methods of use | GENENTECH INC | 2014-01-08 | — | — | CN | disclosed |
| EP-2336132-B1 | MORPHOLINOPURINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2014-01-01 | — | — | EP | disclosed |
| US-8309546-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| CN-102459272-A | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use | GENENTECH INC | 2012-05-16 | — | — | CN | disclosed |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8097622-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-17 | — | — | US | disclosed |
| CN-102245607-A | Morpholinopurine derivative | DAIICHI SANKYO CO LTD | 2011-11-16 | — | — | CN | disclosed |
| EP-2336132-A1 | MORPHOLINOPURINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| CN-102105474-A | Purine PI3K inhibitor compounds and methods of use | GENENTECH INC | 2011-06-22 | — | — | CN | disclosed |
| WO-2010114494-A1 | 8-SUBSTITUTED-2-MORPHOLINO PURINES FOR USE AS PI3K AND/OR MTOR INHIBITORS IN THE TREATMENT OF PROLIFERATIVE DISORDERS | S*BIO PTE LTD (SG) | 2010-10-07 | — | — | WO | disclosed |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | PIK3CD 46/4885PIK3CA 22/4885PIK3CB 102/4885 |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | PIK3CD 46/4885PIK3CA 22/4885PIK3CB 102/4885 |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DNMT1, MGMT, DCK | PIK3CD 495/4885PIK3CA 607/4885PIK3CB 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.